Leukemia - Table of Contents alert Volume 29 Issue 2

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 29, Issue 2 (February 2015) In this issue Review Concise Review Original Articles Letters to the Editor Corrigenda Also new AOP Sign up for e-alerts Recommend to your library Web feed Follow on Twitter Subscribe Advertisement Chronic Lymphocytic Leukemia: Recent advances in biology and therapy  Access this new Collection from Leukemia available free online for six months. Produced with support from: Janssen Pharmaceuticals Companies of Johnson & Johnson   Review Top Myelodysplasia is in the niche: novel concepts and emerging therapies OPEN E Bulycheva, M Rauner, H Medyouf, I Theurl, M Bornhäuser, L C Hofbauer and U Platzbecker Leukemia 2015 29: 259-268; advance online publication, November 14, 2014; 10.1038/leu.2014.325 Abstract | Full Text Concise Review Top Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications P Sportoletti, E Varasano, R Rossi, A Mupo, E Tiacci, G Vassiliou, M P Martelli and B Falini Leukemia 2015 29: 269-278; advance online publication, September 2, 2014; 10.1038/leu.2014.257 Abstract | Full Text Original Articles Top MOLECULAR TARGETS FOR THERAPY Activating c-KIT mutations confer oncogenic cooperativity and rescue RUNX1/ETO-induced DNA damage and apoptosis in human primary CD34+ hematopoietic progenitors OPEN C Wichmann, I Quagliano-Lo Coco, Ö Yildiz, L Chen-Wichmann, H Weber, T Syzonenko, C Döring, C Brendel, K Ponnusamy, A Kinner, C Brandts, R Henschler and M Grez Leukemia 2015 29: 279-289; advance online publication, June 4, 2014; 10.1038/leu.2014.179 Abstract | Full Text ACUTE LEUKEMIAS Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia K Koh, D Tomizawa, A Moriya Saito, T Watanabe, T Miyamura, M Hirayama, Y Takahashi, A Ogawa, K Kato, K Sugita, T Sato, T Deguchi, Y Hayashi, J Takita, Y Takeshita, M Tsurusawa, K Horibe, S Mizutani and E Ishii Leukemia 2015 29: 290-296; advance online publication, June 3, 2014; 10.1038/leu.2014.172 Abstract | Full Text Genomic profiling of thousands of candidate polymorphisms predicts risk of relapse in 778 Danish and German childhood acute lymphoblastic leukemia patients OPEN A Wesołowska-Andersen, L Borst, M D Dalgaard, R Yadav, K K Rasmussen, P S Wehner, M Rasmussen, T F Ørntoft, I Nordentoft, R Koehler, C R Bartram, M Schrappe, T Sicheritz-Ponten, L Gautier, H Marquart, H O Madsen, S Brunak, M Stanulla, R Gupta and K Schmiegelow Leukemia 2015 29: 297-303; advance online publication, July 3, 2014; 10.1038/leu.2014.205 Abstract | Full Text PKCζ and PKMζ are overexpressed in TCF3-rearranged paediatric acute lymphoblastic leukaemia and are associated with increased thiopurine sensitivity OPEN S A Hartsink-Segers, J J Beaudoin, M W J Luijendijk, C Exalto, R Pieters and M L Den Boer Leukemia 2015 29: 304-311; advance online publication, July 3, 2014; 10.1038/leu.2014.210 Abstract | Full Text Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center R B Walter, M Othus, A K Burnett, B Löwenberg, H M Kantarjian, G J Ossenkoppele, R K Hills, F Ravandi, T Pabst, A Evans, S R Pierce, M-C Vekemans, F R Appelbaum and E H Estey Leukemia 2015 29: 312-320; advance online publication, August 12, 2014; 10.1038/leu.2014.242 Abstract | Full Text CHRONIC LYMPHOCYTIC LEUKEMIA Basal Ca2+ signaling is particularly increased in mutated chronic lymphocytic leukemia A F Muggen, S Y Pillai, L P Kil, M C van Zelm, J J M van Dongen, R W Hendriks and A W Langerak Leukemia 2015 29: 321-328; advance online publication, June 11, 2014; 10.1038/leu.2014.188 Abstract | Full Text Recurrent mutations refine prognosis in chronic lymphocytic leukemia P Baliakas, A Hadzidimitriou, L-A Sutton, D Rossi, E Minga, N Villamor, M Larrayoz, J Kminkova, A Agathangelidis, Z Davis, E Tausch, E Stalika, B Kantorova, L Mansouri, L Scarfò, D Cortese, V Navrkalova, M J J Rose-Zerilli, K E Smedby, G Juliusson, A Anagnostopoulos, A M Makris, A Navarro, J Delgado, D Oscier, C Belessi, S Stilgenbauer, P Ghia, S Pospisilova, G Gaidano, E Campo, J C Strefford, K Stamatopoulos and R Rosenquist on behalf of the European Research Initiative on CLL (ERIC) Leukemia 2015 29: 329-336; advance online publication, June 19, 2014; 10.1038/leu.2014.196 Abstract | Full Text IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events D Rizzo, J Chauzeix, F Trimoreau, J B Woillard, F Genevieve, A Bouvier, J Labrousse, C Poli, E Guerin, N Dmytruk, L Remenieras, J Feuillard and N Gachard Leukemia 2015 29: 337-345; advance online publication, June 19, 2014; 10.1038/leu.2014.198 Abstract | Full Text Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia R Mani, Y Mao, F W Frissora, C-L Chiang, J Wang, Y Zhao, Y Wu, B Yu, R Yan, X Mo, L Yu, J Flynn, J Jones, L Andritsos, S Baskar, C Rader, M A Phelps, C-S Chen, R J Lee, J C Byrd, L J Lee and N Muthusamy Leukemia 2015 29: 346-355; advance online publication, June 20, 2014; 10.1038/leu.2014.199 Abstract | Full Text The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting T Vaisitti, V Audrito, S Serra, R Buonincontri, G Sociali, E Mannino, A Pagnani, A Zucchetto, E Tissino, C Vitale, M Coscia, C Usai, C Pepper, V Gattei, S Bruzzone and S Deaglio Leukemia 2015 29: 356-368; advance online publication, July 3, 2014; 10.1038/leu.2014.207 Abstract | Full Text MINIMAL RESIDUAL DISEASE A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR OPEN H White, L Deprez, P Corbisier, V Hall, F Lin, S Mazoua, S Trapmann, A Aggerholm, H Andrikovics, S Akiki, G Barbany, N Boeckx, A Bench, M Catherwood, J-M Cayuela, S Chudleigh, T Clench, D Colomer, F Daraio, S Dulucq, J Farrugia, L Fletcher, L Foroni, R Ganderton, G Gerrard, E Gineikienė, S Hayette, H El Housni, B Izzo, M Jansson, P Johnels, T Jurcek, V Kairisto, A Kizilors, D-W Kim, T Lange, T Lion, K M Polakova, G Martinelli, S McCarron, P A Merle, B Milner, G Mitterbauer-Hohendanner, M Nagar, G Nickless, J Nomdedéu, D A Nymoen, E O Leibundgut, U Ozbek, T Pajič, H Pfeifer, C Preudhomme, K Raudsepp, G Romeo, T Sacha, R Talmaci, T Touloumenidou, V H J Van der Velden, P Waits, L Wang, E Wilkinson, G Wilson, D Wren, R Zadro, J Ziermann, K Zoi, M C Müller, A Hochhaus, H Schimmel, N C P Cross and H Emons Leukemia 2015 29: 369-376; advance online publication, July 18, 2014; 10.1038/leu.2014.217 Abstract | Full Text Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse T Köhnke, D Sauter, K Ringel, E Hoster, R P Laubender, M Hubmann, S K Bohlander, P M Kakadia, S Schneider, A Dufour, M-C Sauerland, W E Berdel, T Büchner, B Wörmann, J Braess, W Hiddemann, K Spiekermann and M Subklewe Leukemia 2015 29: 377-386; advance online publication, June 10, 2014; 10.1038/leu.2014.186 Abstract | Full Text IMMUNOLOGY Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity OPEN W K Chan, D Suwannasaen, R E Throm, Y Li, P W Eldridge, J Houston, J T Gray, C-H Pui and W Leung Leukemia 2015 29: 387-395; advance online publication, June 3, 2014; 10.1038/leu.2014.174 Abstract | Full Text Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors J Peccatori, A Forcina, D Clerici, R Crocchiolo, L Vago, M T L Stanghellini, M Noviello, C Messina, A Crotta, A Assanelli, S Marktel, S Olek, S Mastaglio, F Giglio, L Crucitti, A Lorusso, E Guggiari, F Lunghi, M Carrabba, M Tassara, M Battaglia, A Ferraro, M R Carbone, G Oliveira, M G Roncarolo, S Rossini, M Bernardi, C Corti, M Marcatti, F Patriarca, M Zecca, F Locatelli, C Bordignon, K Fleischhauer, A Bondanza, C Bonini and F Ciceri Leukemia 2015 29: 396-405; advance online publication, June 4, 2014; 10.1038/leu.2014.180 Abstract | Full Text Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice P Macor, E Secco, N Mezzaroba, S Zorzet, P Durigutto, T Gaiotto, L De Maso, S Biffi, C Garrovo, S Capolla, C Tripodo, V Gattei, R Marzari, F Tedesco and D Sblattero Leukemia 2015 29: 406-414; advance online publication, June 6, 2014; 10.1038/leu.2014.185 Abstract | Full Text IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia H J Pegram, T J Purdon, D G van Leeuwen, K J Curran, S A Giralt, J N Barker and R J Brentjens Leukemia 2015 29: 415-422; advance online publication, July 9, 2014; 10.1038/leu.2014.215 Abstract | Full Text ONCOGENES, FUSION GENES AND TUMOR SUPPRESSOR GENES A critical role for CRM1 in regulating HOXA gene transcription in CALM-AF10 leukemias A E Conway, J M Haldeman, D S Wechsler and C P Lavau Leukemia 2015 29: 423-432; advance online publication, July 16, 2014; 10.1038/leu.2014.221 Abstract | Full Text TRANSCRIPTIONAL CONTROL AND SIGNAL TRANSDUCTION Survivin modulates genes with divergent molecular functions and regulates proliferation of hematopoietic stem cells through Evi-1 S Fukuda, J Hoggatt, P Singh, M Abe, J M Speth, P Hu, E M Conway, G Nucifora, S Yamaguchi and L M Pelus Leukemia 2015 29: 433-440; advance online publication, June 6, 2014; 10.1038/leu.2014.183 Abstract | Full Text EPIDEMIOLOGY AND VIROLOGY Second cancers and late mortality in Australian children treated by allogeneic HSCT for haematological malignancy A S Nelson, L J Ashton, C M Vajdic, R E Le Marsney, B Daniels, I Nivison-Smith, L Wilcox, A J Dodds and T A O'Brien on behalf of the CAST study investigators Leukemia 2015 29: 441-447; advance online publication, June 25, 2014; 10.1038/leu.2014.203 Abstract | Full Text LYMPHOMA Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma P Satwani, Z Jin, P L Martin, M Bhatia, J H Garvin, D George, S Chaudhury, J Talano, E Morris, L Harrison, J Sosna, M Peterson, O Militano, S Foley, J Kurtzberg and M S Cairo Leukemia 2015 29: 448-455; advance online publication, June 18, 2014; 10.1038/leu.2014.194 Abstract | Full Text Genomic and epigenomic co-evolution in follicular lymphomas M Loeffler, M Kreuz, A Haake, D Hasenclever, H Trautmann, C Arnold, K Winter, K Koch, W Klapper, R Scholtysik, M Rosolowski, S Hoffmann, O Ammerpohl, M Szczepanowski, D Herrmann, R Küppers, C Pott and R Siebert on behalf of the HaematoSys-Project Leukemia 2015 29: 456-463; advance online publication, July 16, 2014; 10.1038/leu.2014.209 Abstract | Full Text The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma S Robinson, P Dreger, D Caballero, P Corradini, C Geisler, M Ghielmini, S Le Gouill, E Kimby, S Rule, U Vitolo, M Dreyling and O Hermine on behalf of the European MCL Network and the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation Leukemia 2015 29: 464-473; advance online publication, July 18, 2014; 10.1038/leu.2014.223 Abstract | Full Text MYELOMA CSNK1α1 mediates malignant plasma cell survival Y Hu, W Song, D Cirstea, D Lu, N C Munshi and K C Anderson Leukemia 2015 29: 474-482; advance online publication, June 25, 2014; 10.1038/leu.2014.202 Abstract | Full Text Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma R Brown, S Yang, C Weatherburn, J Gibson, P J Ho, H Suen, D Hart and D Joshua Leukemia 2015 29: 483-490; advance online publication, July 3, 2014; 10.1038/leu.2014.204 Abstract | Full Text Letters to the Editor Top Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia OPEN S E Fordham, M Cole, J A Irving and J M Allan Leukemia 2015 29: 491-494; advance online publication, September 24, 2014; 10.1038/leu.2014.284 Full Text MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling OPEN K Kollmann, J Nangalia, W Warsch, H Quentmeier, A Bench, E Boyd, M Scott, H G Drexler and A R Green Leukemia 2015 29: 494-497; advance online publication, September 24, 2014; 10.1038/leu.2014.285 Full Text Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib R A Abdelrahman, K H Begna, A Al-Kali, W J Hogan, M R Litzow and A Tefferi Leukemia 2015 29: 498-500; advance online publication, September 25, 2014; 10.1038/leu.2014.286 Full Text Mutational analysis of the DOK2 haploinsufficient tumor suppressor gene in chronic myelomonocytic leukemia (CMML) E Coppin, V Gelsi-Boyer, X Morelli, N Cervera, A Murati, P P Pandolfi, D Birnbaum and J A Nunès Leukemia 2015 29: 500-502; advance online publication, September 25, 2014; 10.1038/leu.2014.288 Full Text The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma R Piva, S Deaglio, R Famà, R Buonincontri, I Scarfò, A Bruscaggin, E Mereu, S Serra, V Spina, D Brusa, G Garaffo, S Monti, M Dal Bo, R Marasca, L Arcaini, A Neri, V Gattei, M Paulli, E Tiacci, F Bertoni, S A Pileri, R Foà, G Inghirami, G Gaidano and D Rossi Leukemia 2015 29: 503-507; advance online publication, October 6, 2014; 10.1038/leu.2014.294 Full Text Diet-induced obesity promotes a myeloma-like condition in vivo S T Lwin, S W Z Olechnowicz, J A Fowler and C M Edwards Leukemia 2015 29: 507-510; advance online publication, October 7, 2014; 10.1038/leu.2014.295 Full Text Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma R Suzuki, T Hideshima, N Mimura, J Minami, H Ohguchi, S Kikuchi, Y Yoshida, G Gorgun, D Cirstea, F Cottini, J Jakubikova, Y-T Tai, D Chauhan, P G Richardson, N C Munshi, T Utsugi and K C Anderson Leukemia 2015 29: 510-514; advance online publication, October 13, 2014; 10.1038/leu.2014.300 Full Text Corrigenda Top Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma J Yang, J He, J Wang, Y Cao, J Ling, J Qian, Y Lu, H Li, Y Zheng, Y Lan, S Hong, J Matthews, M W Starbuck, N M Navone, R Z Orlowski, P Lin, L W Kwak and Q Yi Leukemia 2015 29: 515; 10.1038/leu.2014.265 Full Text DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies A P Im, A R Sehgal, M P Carroll, B D Smith, A Tefferi, D E Johnson and M Boyiadzis Leukemia 2015 29: 516; 10.1038/leu.2014.269 Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.